71 related articles for article (PubMed ID: 8387118)
21. Myelodysplastic syndromes: the pediatric point of view.
Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F
Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of a combination of human recombinant erythropoietin + 13-cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.
Ferrero D; Darbesio A; Giai V; Genuardi M; Dellacasa CM; Sorasio R; Bertini M; Boccadoro M
Br J Haematol; 2009 Feb; 144(3):342-9. PubMed ID: 19036104
[TBL] [Abstract][Full Text] [Related]
23. Thrombocytopenia in myelodysplastic syndromes and myelofibrosis.
Boruchov AM
Semin Hematol; 2009 Jan; 46(1 Suppl 2):S37-43. PubMed ID: 19245933
[TBL] [Abstract][Full Text] [Related]
24. Long-term improvement of hematopoiesis following cyclosporine treatment in a patient with myelodysplastic syndrome.
Berer A; Ohler L; Simonitsch I; Thalhammer R; Lechner K; Geissler K
Wien Klin Wochenschr; 1999 Oct; 111(19):815-8. PubMed ID: 10568013
[TBL] [Abstract][Full Text] [Related]
25. [Therapy of the preleukemic state: effect of androgens on refractory anemia].
Sakurada K; Morioka M; Miyazaki T
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1960-7. PubMed ID: 2838001
[TBL] [Abstract][Full Text] [Related]
26. Differentiating agents + low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome.
Ferrero D; Campa E; Dellacasa C; Campana S; Foli C; Boccadoro M
Haematologica; 2004 May; 89(5):619-20. PubMed ID: 15136232
[TBL] [Abstract][Full Text] [Related]
27. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
[TBL] [Abstract][Full Text] [Related]
28. Treatment of anemia in low-risk myelodysplastic syndromes with amifostine. In vitro testing of response.
Viniou N; Terpos E; Galanopoulos A; Kritikou-Griva E; Akel S; Michalis E; Apostolidou E; Georgiadou D; Kouraklis A; Parharidou A; Kokkini G; Symeonidis A; Anagnostopoulos NI; Christakis JI; Tasiopoulou A; Loukopoulos D; Yataganas X
Ann Hematol; 2002 Apr; 81(4):182-6. PubMed ID: 11976818
[TBL] [Abstract][Full Text] [Related]
29. All-trans retinoic acid in the treatment of myelodysplastic syndromes.
Visani G; Tosi P; Manfroi S; Ottaviani E; Finelli C; Cenacchi A; Bendandi M; Tura S
Leuk Lymphoma; 1995 Oct; 19(3-4):277-80. PubMed ID: 8535219
[TBL] [Abstract][Full Text] [Related]
30. Treatment of low-risk myelodysplastic syndromes with high-dose daily oral cholecalciferol (2000-4000 IU vitamin D(3)).
Molnár I; Stark N; Lovato J; Powell BL; Cruz J; Hurd DD; Mathieu JS; Chen TC; Holick MF; Cambra S; McQuellon RP; Schwartz GG
Leukemia; 2007 May; 21(5):1089-92. PubMed ID: 17344922
[No Abstract] [Full Text] [Related]
31. Clinical features and prognosis of refractory myelodysplastic anemias: a Japanese Cooperative Study.
Yoshida Y; Oguma S; Uchino H; Maekawa T
Nihon Ketsueki Gakkai Zasshi; 1987 Feb; 50(1):37-45. PubMed ID: 3591236
[No Abstract] [Full Text] [Related]
32. Primary myelodysplastic syndrome: treatment of 6 patients with 13-cis retinoic acid.
Kerndrup G; Bendix-Hansen K; Pedersen B; Ellegaard J; Hokland P
Scand J Haematol Suppl; 1986; 45():128-32. PubMed ID: 3457443
[No Abstract] [Full Text] [Related]
33. [Refractory anemias].
Efira A; Azerad MA
Rev Med Brux; 2013 Sep; 34(4):323-7. PubMed ID: 24195247
[TBL] [Abstract][Full Text] [Related]
34. Acute myelogenous leukemia of unfavourable prognosis treated with retinoic acid, vitamin D3, alpha-interferon and low doses of cytosine arabinoside.
Robèrt KH; Hellström E; Einhorn S; Gahrton G
Scand J Haematol Suppl; 1986; 44():61-74. PubMed ID: 3008320
[No Abstract] [Full Text] [Related]
35. Management of patients with myelodysplastic syndromes.
Noël P
Mayo Clin Proc; 1991 May; 66(5):485-97. PubMed ID: 2030615
[TBL] [Abstract][Full Text] [Related]
36. Effect of 13-cis-retinoic acid on survival of patients with myelodysplastic syndrome.
Clark RE; Jacobs A; Lush CJ; Smith SA
Lancet; 1987 Apr; 1(8536):763-5. PubMed ID: 2882180
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndrome treatment with danazol and cis-retinoic acid.
Letendre L; Levitt R; Pierre RV; Schroeder G; Krook JA; Mailliard JE; Morton RF; Tschetter LK
Am J Hematol; 1995 Apr; 48(4):233-6. PubMed ID: 7717370
[TBL] [Abstract][Full Text] [Related]
38. 13-cis-retinoic acid in myelodysplastic syndromes.
Greenberg BR; Buzaid AC; Meyskens FL
J Clin Oncol; 1986 Aug; 4(8):1282. PubMed ID: 3525772
[No Abstract] [Full Text] [Related]
39. All-trans retinoic acid improves erythropoiesis in myelodysplastic syndromes: a case report.
Visani G; Cenacchi A; Tosi P; Finelli C; Fogli M; Gamberi B; Martinelli G; Tura S
Br J Haematol; 1992 Jul; 81(3):444-6. PubMed ID: 1390219
[No Abstract] [Full Text] [Related]
40. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders.
Koeffler HP; Heitjan D; Mertelsmann R; Kolitz JE; Schulman P; Itri L; Gunter P; Besa E
Blood; 1988 Mar; 71(3):703-8. PubMed ID: 3278754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
